Real-World study tests Anti-HER2 drugs in egyptian breast cancer patients

NCT ID NCT07416409

Completed Knowledge-focused Sponsor: Deraya University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how well anti-HER2 drugs work in Egyptian women with HER2-positive breast cancer. Researchers followed 80 patients who received either one drug (trastuzumab) or a combination (trastuzumab plus pertuzumab or lapatinib) as part of their regular care. The goal was to see how these treatments affect survival and side effects in a real-world setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-HER2 drugs (trastuzumab, pertuzumab, lapatinib)
What this could lead to: If successful, this study could show how well these drugs work in a specific population, helping doctors tailor treatment for Egyptian patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by factors like patient health and treatment choices. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm HER2 positive breast carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS HER2-POSITIVE BREAST CANCER METASTATIC BREAST CANCER ONCOLOGY

Contacts and locations

Locations

Dar Al-Salam Cancer Hospital

Cairo, Menia Governorate, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.